Efficiency of treatment of laryngopharyngeal reflux with proton pump inhibitors depending on the CYP2C19 polymorphism
https://doi.org/10.21518/2079-701X-2021-21-2-35-43
Abstract
Introduction. A treatment for LFR for many years, the superiority of PPIs over placebos is still controversial. Of particular clinical importance is the metabolic rate of PPIs in hepatocytes using the cytochrome P450 system with the participation of the isoenzyme CYP2C19 and partially CYP3A4
Аim. We set a goal to study the efficacy of omeprazole 20 mg in the treatment of LFR symptoms without esophageal syndrome in patients with gastroesophageal reflux (GERD), depending on the polymorphism of the CYP2C19 genotype.
Мaterials and мethods. After the exclusion criteria, 100 people took part in the study, 94 people completed the study.
Results. According to the results, 26.6% of patients in the study group (residents of the Moscow region) with LFR symptoms without esophageal syndrome belong to fast metabolizers of CYP2C19, 4.2% to ultrafast metabolizers, 52.1% to normal metabolizers, 16% to intermediate metabolizers and 1.1% to slow CYP2C19.
Conclusions. In patients with a rapid metabolism, within 1 month after discontinuation of omeprazole, it is necessary to increase the amount of omeprazole 20 mg intake up to 2 times a day in the morning and in the evening and reduce the duration of treatment to 6 weeks.
About the Authors
I. B. Angotoeva
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Irina B. Angotoeva - Cand. Sci. (Med.), Associate Professor of Otorhinolaryngology Department.
2/1, Bldg. 1, Barrikadnaya St., Moscow, 125993.
N. P. Denisenko
Research Institute of Molecular and Personalised Medicine
Russian Federation
Russian Federation
Natalia P. Denisenko - Cand. Sci. (Med.), Head of Personalized Medicine Department, Research Institute of Molecular and Personalised Medicine.
7, Bldg. 2, 2nd Botkin Рroezd, Moscow, 125284.
D. A. Sychev
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Dmitry A. Sychev - Corr. Member RAS, Dr. Sci. (Med.), Рrofessor, Head of Clinical Pharmacology and Therapy Departmen, Russian Medical Academy of Continuous Professional Education.
2/1, Bldg. 1, Barrikadnaya St., Moscow, 125993.
E. V. Schepkina
Russian Аcademy of National Economy and Public Administration under the President of the Russian Federation; Limited Liability Company “Techdepartament”;
Russian Federation
Russian Federation
Еlena V. Schepkina - Cand. Sci. (Sociol.), Deputy Head of Statistics and Consolidated Contingent Department, Russian Аcademy of National Economy and Public Administration under the President of the Russian Federation; Director of Statistics, Limited Liability Company “Techdepartament”.
82, Vernadsky Ave., Moscow, 119571; 2, Вldg. 1, Herman Titov St., Khimki, 141407.
M. M. Magomedova
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Madina M. Magomedova - Resident Second Year of Education, Russian Medical Academy of Continuous Professional Education.
2/1, Bldg. 1, Barrikadnaya St., Moscow, 125993.
References
1. Campagnolo A.M., Priston J., Thoen R.H., Medeiros T., Assunção A.R. Laryngopharyngeal reflux: diagnosis, treatment, and latest research Int Arch Otorhinolaryngol. 2014;18(2):184–191. https://doi.org/10.1055/s-0033-1352504.
2. Ford C.N. Evaluation and management of laryngopharyngeal reflux. JAMA. 2005;294(12):1534–1540. https://doi.org/10.1001/jama.294.12.1534.
3. Hom C., Vaezi M.F. Extra-esophageal Manifestations of Gastroesophageal Reflux Disease: Diagnosis and Treatment. Drugs. 2013;73(12):1281–1295. https://doi.org/10.1007/s40265-013-0101-8.
4. Wang J., Yu Z., Ren J., Xu Y., Zhang Y., Lei L. et al. Effects of pepsin A on heat shock protein 70 response in laryngopharyngeal reflux patients with chronic rhinosinusitis. Acta Otolaryngologica. 2017;137(12):848–854. https://doi.org/10.1080/00016489.2017.1360515.
5. Koufman J.A., Aviv J.E., Casiano R.R., Shaw G.Y. Laryngopharyngeal reflux: position statement of the committee on speech, voice, and swallowing disorders of the American Academy of Otolaryngology–Head and Neck Surgery. Otolaryngol Head Neck Surg. 2002;(127)32–35. https://doi.org/10.1067/mhn.2002.125760.
6. Weijenborg P.W., Savarino E., Kessing B.F., Roman S., Costantini M., Oors J.M. et al. Normal values of esophageal motility after antireflux surgery; a study using high-resolution manometry. Neurogastroenterol Motil. 2015;27(7):929–935. https://doi.org/10.1111/nmo.12554.
7. Dhillon V.K., Akst L.M. How to Approach Laryngopharyngeal Reflux: An Otolaryngology Perspective. Curr Gastroenterol Rep. 2016;18(8):44. https://doi.org/10.1007/s11894-016-0515-z.
8. Savlevich E.L., Kozlov V.S., Angotoeva I.B. The present-day views of the role of palatine tonsils in the immune system and analysis of application of immunotropic drugs in chronic tonsillitis Rossiiskaya otorinolaringologiya = Russian Otorhinolaryngology. 2018;(6):48–55. (In Russ.) Available at: https://entru.org/files/j_rus_LOR_6_2018.pdf.
9. Lechien J.R., Saussez S., Schindler A., Karkos P.D., Hamdan A.L., Harmegnies B. et al. Clinical outcomes of laryngopharyngeal reflux treatment: A systematic review and meta-analysis. Laryngoscope. 2019;129(5):1174–1187. https://doi.org/10.1002/lary.27591.
10. Lechien J.R., Mouawad F., Barillari M.R., Nacci A., Khoddami S.M., Nand E. et al. Treatment of laryngopharyngeal reflux disease: A systematic review. World J Clin Cases. 2019;7(19):2995–3011. https://doi.org/10.12998/wjcc.v7.i19.2995.
11. Francis D.O. Bench to trench: how evidence and guidelines shape health care policy and practice. Otolaryngol Head Neck Surg. 2013;149(3):356–359. https://doi.org/10.1177/0194599813491228.
12. Lechien J.R., Dapri G., Dequanter D., Rodriguez Ruiz A., Marechal M.T., De Marrez L.G. et al. Surgical Treatment for Laryngopharyngeal Reflux Disease: A Systematic Review. JAMA Otolaryngol Head Neck Surg. 2019;145(7):655–666. https://doi.org/10.1001/jamaoto.2019.0315.
13. Danielson P.B. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab. 2002;3(6):561–597. https://doi.org/10.2174/1389200023337054.
14. Lima J.J., Thomas C.D., Barbarino J., Desta Z., Van Driest S.L., El Rouby N. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417–1423. https://doi.org/10.1002/cpt.2015.
15. Sim S.C., Risinger C., Dahl M.L., Aklillu E., Christensen M., Bertilsson L., Ingelman-Sundberg M. A сommon novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79(1):103–113. https://doi.org/10.1016/j.clpt.2005.10.002.
16. Klotz U., Schwab M., Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol. 2004;95(1):2–8. https://doi.org/10.1111/j.1600-0773.2004.pto950102.x.
17. Yang J.C., Lin C.J. CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection. Expert Opin Drug Metab Toxicol. 2010;6(1):29–41. https://doi.org/10.1517/17425250903386251.
18. Leonova M.V. Pharmacogenetics of proton pump inhibitors. Medical advice. 2015;(17):96–103. https://doi.org/10.21518/2079-701X-2015-17-96-103.
19. Koufman J.A. The otolaryngologic manifestation of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope. 1991;10(2 Suppl.):1–78. https://doi.org/10.1002/lary.1991.101.s53.1.
20. Belafsky P.C., Postma G.N., Koufman J.A. Laryngopharyngeal reflux symptoms improve before changes in physical findings. Laryngoscope. 2001;111(6):979–981. https://doi.org/10.1097/00005537-200106000-00009.
21. Belafsky P.C., Postma G.N., Koufman J.A. Validity and reliability of the reflux symptom index (RSI). J Voice. 2002;16(2):274–277. https://doi.org/10.1016/s0892-1997(02)00097-8.
22. Schenk B.E., Kuipers E.J., Klinkenberg-Knol E.C., Festen H.P., Jansen E.H., Tuynman H.A. et al. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol. 1997;92(11):1997–2000. Available at: https://pubmed.ncbi.nlm.nih.gov/9362179.
23. Sychev D.A., Shprakh V.V., Kitaeva E.Yu., Mirzaev K.B., Mickhalevich I.M. Genetic and non-genetic factors of laboratory resistance to clopidogrel in patients with ischemic stroke. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2019;(3–2):45–52. (In Russ.) https://doi.org/10.17116/jnevro201911903245.
24. Sibbing D., Gebhard D., Koch W., Braun S., Stegherr J., Morath T. et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost. 2010;8(8):1685–1693. https://doi.org/10.1111/j.1538-7836.2010.03921.x.
25. Mega J., Close S., Wiviott S., Shen L., Hockett R.D., Brandt J.T. et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354–624. https://doi.org/10.1056/NEJMoa0809171.
26. Luo H.R., Poland R.E., Lin K.M., Wan Y.J. Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study. Clin Pharmacol Ther. 2006;80(1):33–40. https://doi.org/10.1016/j.clpt.2006.03.003.
27. Giusti B., Gori A.M., Marcucci R., Saracini C., Sestini I., Paniccia R. et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drugeluting coronary stent thrombosis. Am J Cardiol. 2009;103(6):806–811. https://doi.org/10.1016/j.amjcard.2008.11.048.
28. Bonello L., Armero S., Ait Mokhtar O., Mancini J., Aldebert P., Saut N. et al. Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism. J Am Coll Cardiol. 2010;56(20):1630–1636. https://doi.org/10.1016/j.jacc.2010.07.004.
29. Mirzaev K.B., Sychev D.A., Karkischenko V.N., Grachev A.V., Knyazev G.P., Kazakov R.E., Korasev A.V. CYP2C19*2, CYP2C19*3, CYP2C19*17 allele and genotype frequencies in clopidogrel-treated patients with coronary heart disease from the Russian population. Biomedicine = Journal Biomed. 2013;(1):117–122. (In Russ.) Available at: https://journal.scbmt.ru/jour/article/viewFile/248/153.
30. Powell J., O’Hara J., Wilson J.A. Are persistent throat symptoms atypical features of gastric reflux and should they be treated with proton pump inhibitors? BMJ. 2014;349:g5813. https://doi.org/10.1136/bmj.g5813.
31. Kowalik K., Krzeski A. The role of pepsin in the laryngopharyngeal reflux. Otolaryngol Pol. 2017;71(6):7–13. https://doi.org/10.5604/01.3001.0010.7194.
32. Adhami T., Goldblum J.R., Richter J.E., Vaezi M.F. The role of gastric and duodenal agents in laryngeal injury: an experimental canine model. Am J Gastroenterol. 2004;99(11):2098–2106. Available at: https://pubmed.ncbi.nlm.nih.gov/15554987.
33. Loughlin C.J., Koufman J.A., Averill D.B., Cummins M.M., Kim Y.J., Little J.P. et al. Acid-induced laryngospasm in a canine model. Laryngoscope.1996;106(12): 1506–1509. https://doi.org/10.1097/00005537-199612000-00012.
34. Franco R.A. Laryngopharyngeal Reflux. UpToDate. 2017. Available at: https://uptodatefree.ir/topic.htm?path=laryngopharyngeal-reflux.
35. Bove M.J., Rosen C. Diagnosis and management of laryngopharyngeal reflux disease. Curr Opin Otolaryngol Head Neck Surg. 2006;14(3):116–123. Available at: https://pubmed.ncbi.nlm.nih.gov/16728885.
36. Blyume Kh., Donat F., Varnke A., Shug B.S. Pharmacokinetic drug interactions involving proton pump inhibitors. RMJ. 2009;(9):622. (In Russ.) Available at: https://www.rmj.ru/articles/gastroenterologiya/Farmakokineticheskie_lekarstvennye_vzaimodeystviya s_uchastiem_ingibitorov_protonnoy_pompy.
37. Pinto-Sanchez M., Yuan Y., Hassan A., Bercik P., Moayyedi P. Proton pump inhibitors for functional dyspepsia. Cochrane Database of Systematic Reviews. 21;11(11):CD011194. https://doi.org/10.1002/14651858.CD011194.pub3.
Review
For citations:
Angotoeva IB, Denisenko NP, Sychev DA, Schepkina EV, Magomedova MM. Efficiency of treatment of laryngopharyngeal reflux with proton pump inhibitors depending on the CYP2C19 polymorphism. Meditsinskiy sovet = Medical Council. 2021;(21-2):35-43. (In Russ.) https://doi.org/10.21518/2079-701X-2021-21-2-35-43
Views:
1431
Email this article 